VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Is it prime-time for CAR-T in myeloma?

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, gives an overview of the CAR T-cell therapy landscape in multiple myeloma (MM) and what we can expect to see in the future. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter